TP53 and small cell lung carcinoma: Two clinical trials, NCT00049218 (phase I/II) and NCT00617409 (phase II), are focused on evaluating the effectiveness of chemotherapy followed by the administration of the Ad.p53-DC vaccine in patients with extensive-stage SCLC [110,111].